

VYVGART is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-AChR antibody positive.¹ To acquire VYVGART, please contact the following specialty distributors or specialty pharmacies.

Specialty Distributors

	P: PHONE F: FAX	EMAIL	WEBSITE
McKesson Plasma and Biologics	P: 877-625-2566 F: 888-752-7626	mpborders@mckesson.com	connect.mckesson.com
McKesson Specialty Health (for multi-specialty customers)	P: 855-477-9800 F: 800-800-5673	mshcustomercare-mspl@mckesson.com	mscs.mckesson.com
McKesson Specialty Health (for oncology customers)	P: 800-482-6700 F: 855-824-9489	oncologycustomersupport@mckesson.com	mscs.mckesson.com
CuraScript SD	P: 877-599-7748 F: 800-862-6208	customer.service@curascript.com	N/A
Cardinal Health Specialty Pharmaceutical Distribution	P: 866-476-1340 F: 614-553-6301	gmb-spd-csorderentry@cardinalhealth.com	orderexpress.cardinalhealth.com or specialtyonline.cardinalhealth.com
ASD Healthcare	P: 800-746-6273 F: 800-547-9413	service@asdhealthcare.com	asdhealthcare.com
Oncology Supply	P: 800-633-7555 F: 800-248-8205	service@oncologysupply.com	oncologysupply.com
Besse Medical	P: 800-543-2111 F: 800-543-8695	service@besse.com	besse.com
BioCareSD	P: 800-304-3064 F: 602-850-6215	order@biocaresd.com	biocaresd.com

Specialty Pharmacies

	P: PHONE F: FAX	EMAIL	WEBSITE
Accredo Specialty Pharmacy	P: 888-200-2811 F: 866-233-7151	N/A	accredo.com
Option Care Health	P: 833-812-0669 F: 855-211-5843	oc-argenxreferral@optioncare.com	optioncarehealth.com
Soleo Health	P: 844-503-0912 F: 844-506-6185	mgtherapy@soleohealth.com	soleohealth.com
CVS Specialty	P: 800-237-2767 F: 800-323-2445	N/A	cvsspecialty.com
AcariaHealth Pharmacy	P: 800-511-5144 F: 877-541-1503	N/A	acariahealth.envolvehealth.com
Optum	P: 877-342-9352 F: 877-542-9352	N/A	optumrx.com

Code Type	Code	Description
NDC ¹	73475-3041-5	400 mg of efgartigimod alfa-fcab in 20 mL (20 mg/mL)
HCPCS code ²	J9332	Injection, efgartigimod alfa-fcab, 2 mg

Important Safety Information (see additional ISI on bottom of page 2)

WARNINGS AND PRECAUTIONS

Infection

VYVGART may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% for VYVGART vs 5% for placebo) and respiratory tract infection (33% for VYVGART vs 29% for placebo). Patients on VYVGART vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay VYVGART administration in patients with an active infection until the infection is resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART until the infection has resolved.

Please see full Prescribing Information.

References: 1. VYVGART. Prescribing information. argenx US Inc; 2022. 2. Centers for Medicare & Medicaid Services (CMS). July 2022 alpha-numeric HCPCS file. Accessed May 3, 2022. <https://www.cms.gov/files/document/2022-hcpcs-application-summary-quarter-1-2022-drugs-and-biologicals.pdf>

Additional Resources

If you have additional questions about **VYVGART**, please contact **My VYVGART Path** at **1-833-MY-PATH-1 (1-833-697-2841)** where you can be connected to the appropriate resource.



Storage and Handling Requirements

VYVGART (efgartigimod alfa-fcab) injection is a preservative free, sterile, colorless to slightly yellow, clear to slightly opalescent solution supplied as 400 mg/20 mL (20 mg/mL) in one single-dose vial per carton (NDC 73475-3041-5).

Store VYVGART vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. **DO NOT FREEZE. DO NOT SHAKE.**

Infusion Site Locator

Click [here](#) to find infusion centers in your area. These centers specialize in infusion treatments and have an experienced staff to help you through the infusion process.

You can access downloadable resources online by clicking [here](#) and scrolling to the bottom of the web page.

Important Safety Information (continued)

Immunization

Immunization with vaccines during VYVGART treatment has not been studied; the safety with live or live-attenuated vaccines and the response to immunization with any vaccine are unknown. Because VYVGART causes a reduction in immunoglobulin G (IgG) levels, vaccination with live-attenuated or live vaccines is not recommended during VYVGART treatment. Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART.

Hypersensitivity Reactions

Hypersensitivity reactions, including rash, angioedema, and dyspnea, were observed with VYVGART. In clinical trials, hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration, and did not lead to treatment discontinuation. Monitor patients during administration and for 1 hour thereafter for clinical signs and symptoms of hypersensitivity reactions. If a hypersensitivity reaction occurs during administration, discontinue VYVGART infusion and institute appropriate supportive measures if needed.

Adverse Reactions

The most common ($\geq 10\%$) adverse reactions with VYVGART were respiratory tract infection, headache, and urinary tract infection.

USE IN SPECIFIC POPULATIONS

Pregnancy

As VYVGART is expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to infants exposed to VYVGART in utero.

Lactation

There is no information regarding the presence of VYVGART in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VYVGART and any potential adverse effects on the breastfed infant from VYVGART or from the underlying maternal condition.

Indication

VYVGART[®] (efgartigimod alfa-fcab) is indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

Please see full Prescribing Information.

You may report side effects to the US Food and Drug Administration by visiting <http://www.fda.gov/medwatch> or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).